Summary
Stryker Corporation's 2001 10-K report highlights a year of significant growth, with net sales increasing by 14% to $2.6 billion. This growth was driven by a robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company successfully navigated a dynamic market, marked by strategic acquisitions and a strong focus on research and development, evidenced by a 16% increase in R&D expenses. Financially, Stryker demonstrated improved profitability and liquidity. Net earnings saw a substantial increase of 21% to $267 million. The company also enhanced its financial flexibility through refinancing its credit facilities. Despite ongoing healthcare cost containment measures, Stryker's commitment to innovation and its broad product portfolio position it well for continued expansion in the specialty surgical and medical products market.
Key Highlights
- 1Stryker reported a 14% increase in net sales, reaching $2.6 billion in 2001, driven by strong performance in both Orthopaedic Implants and MedSurg Equipment segments.
- 2Net earnings grew by 21% to $267 million, demonstrating improved profitability.
- 3Research, Development, and Engineering (R&D&E) expenses increased by 16% to $142.1 million, underscoring the company's commitment to innovation and new product development.
- 4The company successfully refinanced its credit facilities in December 2001, establishing $1 billion in unsecured credit facilities, enhancing financial flexibility.
- 5International sales represented 35% of total revenues in 2001, with growth driven by strong performance in Orthopaedic Implants and MedSurg Equipment.
- 6Stryker received Humanitarian Device Exemption (HDE) status for its OP-1 Implant from the U.S. FDA in late 2001, for specific long bone nonunion indications.
- 7The company continued its strategic acquisition strategy, including the acquisition of an Italian distributor to consolidate its distribution network in Italy.